Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.